Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Jian Zhou was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 15
Laekna, Inc., Annual General Meeting, Jun 05, 2026 Laekna, Inc., Annual General Meeting, Jun 05, 2026, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai, china, Hong Kong Tillkännagivande • Mar 06
Laekna, Inc. to Report Fiscal Year 2025 Results on Mar 18, 2026 Laekna, Inc. announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 18, 2026 Tillkännagivande • Jan 14
Laekna, Inc. Announces That the U.S. Food and Drug Administration Has Accepted Its Investigational New Drug Application for LAE118 The board of directors of Laekna, Inc. announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for LAE118, a novel PI3K a pan-mutant selective inhibitor for the treatment of patients with PIK3CA-mutant solid tumors. The Company will work closely with the regulatory authorities to complete the application. Building on its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the Company aims to bring this precision therapy to cancer patients who are in need of novel treatment options. Tillkännagivande • Jan 02
Laekna, Inc. Commences Study Recruitment in Phase I Single Ascending Dose Study of LAE103 The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I single ascending dose study of LAE103, an internally discovered monoclonal antibody against ActRIIB, in Australia. As of the date of this announcement, first subject has been dosed. The SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026. The Group targets to bring this precision therapy to cardiovascular and metabolic diseases with high unmet medical needs, such as obesity, sarcopenia and heart failure. Tillkännagivande • Sep 18
Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million. Laekna, Inc. has completed a Follow-on Equity Offering in the amount of HKD 586.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,000,000
Price\Range: HKD 16.3
Discount Per Security: HKD 0.26
Transaction Features: Subsequent Direct Listing Tillkännagivande • Sep 11
Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million. Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 586.8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 36,000,000
Price\Range: HKD 16.3
Discount Per Security: HKD 0.26
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jul 29
Laekna, Inc. to Report First Half, 2025 Results on Aug 13, 2025 Laekna, Inc. announced that they will report first half, 2025 results on Aug 13, 2025 Tillkännagivande • Jun 30
Laekna, Inc. Submits Investigational New Drug Application to the U.S. Food and Drug Administration The board of directors of Laekna, Inc. announced that the Group has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LAE103, an internally discovered monoclonal antibody against ActRIIB for the treatment of patients with sarcopenic obesity and muscle related disease. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to metabolic patients who are in need of novel treatment options. The Group plans to separately evaluate the efficacy and safety of monoclonal antibodies targeting at ActRIIA and ActRIIB in humans. Tillkännagivande • Jun 24
Laekna Presents Clinical and Pre-clinical Studies Results of LAE102, LAE103 and LAE123 Laekna announced that the results of: i) the phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). ADA is one of the global leading conferences dedicated to diabetes research, care, and innovation and has taken place in Chicago, USA, from June 20 to 23 this year. Professor Xuening LI, Zhongshan Hospital affiliated to Fudan University,Principal Investigator of the Phase I Clinical Trial of LAE102 in China. At the ADA Scientific Sessions, Laekna showcased LAE102, LAE102, LAE 103, and LAE123 - an innovative portfolio targeting the ActRII pathway - highlighting team's extensive expertise and leadership in this field. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively. Tillkännagivande • Jun 23
Laekna, Inc. Announces Results of Phase I Sad Study of Lae102 Laekna, Inc. announced that the results of (i) phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and (ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association (ADA). Presentations details are as follows: Poster No.1. Abstract Number: 2205-LB, Title: First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy volunteers, Time: Sunday, June 22, 2025, 12:30 p.m.-13:30 p.m. CST, Location: Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA. Highlights: A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m2 and 23.08 kg/m2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous (IV) and subcutaneous (SC) cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events (TEAEs) leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass, while LAE103 had less effect. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123. This positions LAE102 as a promising drug candidate for achieving quality weight control. Tillkännagivande • May 13
Laekna, Inc., Annual General Meeting, Jun 03, 2025 Laekna, Inc., Annual General Meeting, Jun 03, 2025, at 09:00 China Standard Time. Location: 5f, 987 cailun road, pudong, shanghai China Tillkännagivande • Mar 26
Laekna, Inc. Commences Study Recruitment in Phase I Multiple Ascending Dose Study of Lae102 for the Treatment of Obity The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I multiple ascending dose study of LAE102 in China for the treatment of obesity. As of the date of this announcement, the first visit for the first subject has been completed. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control. Tillkännagivande • Mar 10
Laekna, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025 Laekna, Inc. announced that they will report fiscal year 2024 results on Mar 24, 2025 Tillkännagivande • Jan 13
Laekna, Inc. Announces Completion of A Successful Phase I Single Ascending Dose Study of Lae102 for the Treatment of Obesity The board of directors of Laekna, Inc. announced that the Group has successfully completed the phase I single ascending dose study of LAE102 for the treatment of obesity. The SAD Study enrolled a total of 64 healthy subjects with an average BMI of 23.2+-2.2 kg/m2, including 5 intravenous cohorts and 3 subcutaneous cohorts. The positive outcomes of the SAD Study results have established a solid foundation for the coming phase I multiple ascending dose study in China as well as the phase I clinical study in collaboration with Eli Lilly & Company in the U.S. The SAD Study data of LAE102 analyzed to date demonstrated an encouraging safety and tolerability profile, with no serious adverse events and no discontinuations due to adverse events. All treatment emergent adverse events reported to date were very well tolerated, with the majority of them being reported as mild (grade 1) lab test abnormality without any clinical symptoms or signs. There is no reported case of diarrhea. Obvious target engagements and expected pharmacodynamic biomarker changes have been observed. Single doses of LAE102 resulted in significant and sustained increasing in activin A level, indicating a robust target engagement. The duration of target engagement correlated to the dose level. The detailed study results will be presented in a scientific conference as soon as possible. The positive SAD Study results support continuing the investigation of LAE102 for thetreatment of obesity. The Group plans to initiate the MAD Study in the first quarter of 2025 and to work closely with Lilly to commence the phase I clinical study in U.S. as soon as possible. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control. Tillkännagivande • Dec 04
Laekna, Inc. Announces All Subjects in Phase I Sad Study of LAE102 Have Been Dosed for the Treatment of Obesity Laekna, Inc. announced that phase I clinical trial of LAE102 is progressing effectively. As of the date of this announcement, all subjects (64 subjects in total of 8 intravenous injection and subcutaneous injection ascending dose cohorts) of the phase I single ascending dose study (the SAD Study) have been dosed. Early signs of target engagements and expected pharmacodynamic biomarker changes have been observed with a generally accepted safety profile. The phase I clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of LAE102, administered both intravenously and subcutaneously, in healthy subjects and overweight/obese subjects. The Group plans to commence the phase I multiple ascending dose study (the MAD Study) right after the completion of the SAD Study in order to further evaluate the tolerability and efficacy to accelerate the clinical and business development of LAE102. The Group targets to bring this precision therapy to overweight and obesity patients who are in need of novel treatment options for achieving quality weight control. Given the challenging macroeconomic environment, it is clear that strict financial discipline is essential to success. The Group has implemented and will continue to implement disciplined development strategy to ensure healthy financial position and stable cash flow performance. It allows the company to fund and accelerate the clinical development of LAE102. Tillkännagivande • Nov 28
Laekna, Inc. Advances LAE123 to Pre-Clinical Candidate Declaration and Initiates an IND-Enabling Study for LAE123 for the Treatment of Severe Diseases The board of directors of Laekna, Inc. announced that the Group has advanced LAE123 to pre-clinical candidate declaration and has initiated an IND-enabling study for LAE123 for the treatment of severe diseases. LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody that can potently block the interaction between ActRIIA/IIB and their ligands, including Myostatin, Activins and Growth/differentiation factors. LAE123 is a strong ActRIIA and ActRIIB blocker which has shown superior potency in cell-based reporter gene assays (RGA), excellent pharmacokinetics and efficacy in animal studies. Dysregulation of ActRII signaling has been implicated in many diseases, such as obesity, sarcopenia, and other severe diseases. Tillkännagivande • Nov 23
Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 235.61696 million. Laekna, Inc. has filed a Follow-on Equity Offering in the amount of HKD 235.61696 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 17,636,000
Price\Range: HKD 13.36
Transaction Features: Subsequent Direct Listing New Risk • Sep 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (CN¥657k revenue, or US$94k). Tillkännagivande • Aug 06
Laekna, Inc. to Report First Half, 2024 Results on Aug 16, 2024 Laekna, Inc. announced that they will report first half, 2024 results on Aug 16, 2024 Tillkännagivande • Jun 26
Laekna, Inc Doses Subject in Phase I Clinical Trial of LAE102 for the Treatment of Obesity The board of directors of Laekna, Inc. announced that the Group has commenced study recruitment in phase I clinical trial of LAE102 in China and first subject has been dosed. The phase I clinical trial of LAE 102 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of the therapy. The Group targets to bring this precision therapy to overweight and obesity patients who are in need of novel treatment options for achieving quality weight control. Tillkännagivande • May 31
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer The board of directors of Laekna, Inc. announced that first patient has been enrolled and the Group has commenced study recruitment in Phase III clinical trial AFFIRM-205 in China for LAE002 (afuresertib, an oral AKT inhibitor) plus fulvestrant (the Combination Therapy) in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) (the Phase III Clinical Trial AFFIRM-205). The Phase III Clinical Trial AFFirM-205 is a multi-center, randomized, double-blind, placebo-controlled pivotal study to further assess the anti-tumor efficacy and safety of the combination therapy. The results of Phase Ib study in the Combination Therapy with 20 patients from U.S. and China has shown promising anti-cancer efficacy with a well-tolerated safety profile. The data of this study have been presented during a poster spotlight session at the 2023 San Antonio Breast Cancer Symposium (SABCS) in December 2023. The company have enrolled 11 additional subjects in this Phase Ib study and further verified the promising anti-cancer efficacy with a well-tolerated safety profile indicated in the earlier stage of the study. The Group plans to present the clinical data of all enrolled patients and the patients with positive biomarker in this Phase Ib study in a scientific conference in second half of 2024. The Group plans to bring this precision therapy to HR+/HER2- LA/mBC patients who are in need of novel treatment options. Tillkännagivande • May 11
Lekna, Inc. Obtains IND Approval from the CDE for LAE102 Laekna, Inc. announced that the Group has obtained the IND approval from the CDE for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of patients with obesity indication. The Group has commenced to coordinate the clinical study of LAE102 and targets to bring this precision therapy to obesity patients who are in need of novel treatment options. LAE102 is a monoclonal antibody against ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and dramatically attenuates lean mass loss induced by GLP1R agonist. This makes LAE102 a drug candidate for achieving quality weight control through reducing fat while keeping muscle mass. Tillkännagivande • Mar 12
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration Laekna, Inc. announced that the Group has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of patients with obesity or metabolic diseases. The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to obesity or metabolic patients who are in need of novel treatment options. Tillkännagivande • Mar 08
Laekna, Inc. to Report Fiscal Year 2023 Results on Mar 26, 2024 Laekna, Inc. announced that they will report fiscal year 2023 results on Mar 26, 2024 Board Change • Mar 05
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). CEO & Executive Chairman Chris Lu is the most experienced director on the board, commencing their role in 2016. Independent Non-Executive Director Jian Zhou was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • Feb 29
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102 Laekna, Inc. announced that the Centre for Drug Evaluation of the National Medical Products Administration of China has accepted the Investigational New Drug (IND) application for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of adult patients with obesity or metabolic diseases. The Company is pleased of the IND application acceptance of LAE102 and will work closely with the regulatory authorities to complete the application. The Company would commence the clinical trial process after obtaining the IND approval and is committed to bring this precision therapy to obesity or metabolic patients who are in need of novel treatment options. Tillkännagivande • Feb 03
Laekna, Inc. Announces Management Changes Laekna, Inc. announced that Ms. Tang Wing Shan Winza has resigned as a joint company secretary of the Company and has ceased to act as an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the ``Listing Rules'') on The Stock Exchange of Hong Kong Limited and the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the ``Process Agent'') with effect from 2 February 2024. Ms. TANG has confirmed that she has no disagreement with the Board and that there are noother matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange. The Board further announces that Ms. Ho Wing Nga (``Ms. HO'') was appointed as the Joint Company Secretary, Authorised Representative, and the Process Agent, with effect from 2 February 2024. Mr. KE Chenyu(``Mr. KE'') will continue acting as the other Joint Company Secretary. Ms. HO has over 25 years of experience in corporate governance services. She obtained a master's degree in corporate governance from the Hong Kong Polytechnic University. Ms. HO is a fellow of both the Hong Kong Chartered Governance Institute (the ``HKCGI'') and The Chartered Governance Institute. She is also a holder of the practitioner's endorsement of HKCGI and a member of The Hong Kong Institute of Directors. Mr. KE was appointed as a joint company secretary of Company in May 2022. Mr. KE joined Group in August 2021 as head of legal, responsible for overseeing legal, regulatory and compliance matters of Company. Prior to joining Group, Mr. KE worked at Kaye Scholer LLP from August 2011 to July 2013. He served as an associate at Benesch, Friedlander, Coplan & Aronoff LLP from September 2013 to July 2014. From August 2015 to August 2021, he served as the legal general manager of Shanghai Fosun High Technology (Group) Co., Limited, a wholly-owned subsidiary of Fosun International Limited, and was responsible for the legal and compliance in healthcare sector. Mr. KE obtained his Bachelor's degree in law from East China University of Political Science and Law in China in July 2007. He obtained his Master's degree in law from Georgetown University Law Center in the United States in May 2015. Tillkännagivande • Jan 29
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China The board of directors of Laekna, Inc. announced that the top-line data of the global MRCT Phase II registrational trial (PROFECTA-II) in both the U.S. and China to treat Platinum-Resistant Ovarian Cancer (PROC) patients with afuresertib plus paclitaxel as follows: The PROFECTA II study (NCT04374630) is a Phase II, randomized, open-label, active-controlled study evaluating the efficacy and safety of afuresertib in combination with paclitaxel versus paclitaxel in women with PROC. The study randomized 150 patients to either investigational or control treatment arm in the U.S. and China. The primary endpoint is progression-free survival, as assessed by investigators. Secondary endpoints include overall survival, objective response rate, and duration of response. The study showed reduced risk of disease progression or death (progression-free survival; PFS) with a HR of 0.744 (95%CI: 0.502-1.102) but missed statistical significance. For biomarker subgroup with phosphor-AKT positive, IHC>1, (37%), study data demonstrated that afuresertib combination arm significantly improved PFS, and the median PFS is 5.4m vs 2.9m with HR of 0.352 (95% CI: 0.,125-0.997). The secondary endpoint overall survival (OS) data observed a positive trend for the biomarker subgroups. The other secondary endpoints showed an increase in objective response rate and longer duration of response. The trial has shown a manageable and tolerable safety profile and adverse events were consistent with the known safety profiles of the individual treatments. The Group will discuss the results with regulatory authorities to identify a registration path for PROC patient populations that may benefit from afuresertib. The details of the trial data will be presented in a medical conference. Tillkännagivande • Jan 16
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer Laekna, Inc. announced that Mr. Chau Kwok Keung has been appointed as the chief financial officer of the Company with effect from January 15, 2024. Mr. CHAU Kwok Keung, aged 47, was independent non-executive Director from June 2023 to January 2024. Mr. Chau has over 20 years of experience in accounting and financial management. Mr. Chau was employed by Arthur Andersen & Co. initially as a staff accountant and he was subsequently promoted to be a senior consultant in the Global Corporate Finance Solution Segment of Arthur Andersen & Co. in March 2002. He was the financial controller of Shanghai Hawei New Materials and Technology Company Limited from June 2002 to August 2003 and the deputy group financial controller of China South City Holdings Limited (a company listed on the Stock Exchange, stock code: 1668) from August 2003 to April 2005. Mr. Chau has also held various positions at China.com Inc. (currently known as Sino Splendid Holdings Limited (a company listed on the Stock Exchange, stock code: 8006) from October 2005 to October 2007, including qualified accountant, chief financial officer, company secretary and authorized representative. Mr. Chau has served as the chief financial officer of Comtec Solar Systems Group Limited (a company listed on the Stock Exchange, stock code: 712) from November 2007 to January 2020 and served as its executive director from June 2008 to January 2020. He has also been an independent director of Bank of Zhangjiakou Co. Ltd. since April 2020. Mr. Chau has served as chief financial officer of BetterLife Holding Limited (a company listed on the Stock Exchange, stock code: 6909) from September 2020 to January 2024 and served as its executive director from December 2020 to January 2024. In the last three years, Mr. Chau had also served as (i) an independent non-executive director and the chairman of the audit committee of Forward Fashion (International) Holdings Company Limited (a company listed on the Stock Exchange, stock code: 2528) from December 2019 to August 2021; (ii) an independent non- executive director and the chairman of the audit committee of China Xinhua Education Group Ltd. (a company listed on the Stock Exchange, stock code: 2779) from October 2017 to November 2022; and (iii) an independent non-executive director and the chairman of the audit committee of Suzhou Basecare Medical Corporation Limited (a company listed on the Stock Exchange, stock code: 2170) from October 2021 to June 2023. He has been serving as (i) an independent director of The9 Limited (a company listed on NASDAQ Global Market, stock code: NCTY) since October 2015; (ii) an independent non-executive director of China Tobacco International (HK) Company Limited(a company listed on the Stock Exchange, stock code: 6055) since December 2018; and (iii) an independent non-executive director and the chairman of the audit committee and remuneration committee of China Infrastructure & Logistics Group Ltd. (a company listed on the Stock Exchange, stock code: 1719) since May 2022. Mr. Chau has been a member of the Association of Chartered Certified Accountants since June 2002, a Chartered Financial Analyst since September 2003 and a member of the Hong Kong Institute of Certified Public Accountants since July 2005. Mr. Chau also obtained a certificate of Qualified Independent Director from the Shanghai Stock Exchange since August 2017, and was certified by China Banking and Insurance Regulatory Commission Zhangjiakou Supervision Branch as qualified director of banking institutions in China since March 2020. Mr. Chau has been a fellow member of the Institute of Public Accountants of Australia and Institute of Financial Accountants since June 2020. Mr. Chau received a Bachelor's degree in Business Administration from the Chinese University of Hong Kong in December 1998. Tillkännagivande • Jan 15
Laekna, Inc. Announces Executive Changes Laekna, Inc. announced that, Mr. CHAU Kwok Keung has tendered his resignation, with effect from January 15, 2024, from his office as an independent non-executive Director, the chairperson of the audit committee ofthe Board, and a member of the remuneration committee of the Board (, due to his other work commitments. Mr. Chau has confirmed that there is no disagreement with the Board and there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. The Board announced that, with effect from January 15, 2024, Mr. ZHOU Jian has been appointed as an independent non-executive Director, the chairperson of the Audit Committee, and a member of the Remuneration Committee. Biographical details of Mr. Zhou are set out as follows: Mr. Zhou Jian, aged 45, joined HSBC Asset Management alternative unit as its Head of Energy Transition Infrastructure China in November 2022. Mr. Zhou is responsible for setting up and managing the HSBC Asset Management China PFM business and managing and overseeing the renewable energy private equity investment activities in China. Prior to joining HSBC, Mr. Zhou worked as Managing Director at Standard Chartered Bank in Hong Kong from August 2019 to October 2022, where he was responsible for leading the Greater China and Korea regional investment banking activities in power, utilities & infrastructure sector. Mr. Zhou also held position as Head of Infrastructure China at Macquarie Capital inShanghai from September 2016 to February 2019. He was an Executive, Vice President and Director in investment banking team at Evercore in Hong Kong from March 2007 to May 2016. Mr. Zhou worked in PricewaterhouseCoopers assurance team in Auckland and Hong Kong from December 2002 to March 2007. Mr. Zhou has been a member of the Chartered Accountants Australia & New Zealand (CA ANZ) since March 2006, a Chartered Financial Analyst of CFA Institute since September 2006 and a member of Hong Kong Institute of Certified Public Accountants (HKICPA) since August 2007. Mr. Zhou received a degree of Bachelor of Commerce (Honours) in Finance from the University of Auckland in May 2002. Board Change • Dec 19
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Keith Chau was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 